GB Sciences’ Cannabinoids Entering Final Preclinical Stage to Study Mechanisms of Action

GB Sciences’ Cannabinoids Entering Final Preclinical Stage to Study Mechanisms of Action
The National Research Council (NRC) of Canada will conduct a final phase of preclinical testing of GB Sciences‘ cannabinoid-based formulations for Parkinson’s disease to determine their mechanisms of action. This final step in testing follows promising results in a fish model of the disease, in which these cannabinoid-based mixtures significantly eased behavioral symptoms linked to the loss of dopamine producing-nerve ... read more
Source: Parkinson’s News TodayPublished on 2020-04-13By Ines Martins, PhD